Pharmacology Biochemistry and Behavior, Год журнала: 2024, Номер unknown, С. 173882 - 173882
Опубликована: Окт. 1, 2024
Язык: Английский
Journal of Anesthesia and Translational Medicine, Год журнала: 2024, Номер 3(3), С. 65 - 75
Опубликована: Июль 11, 2024
Ketamine, a dissociative anesthetic, is widely utilized in both human and veterinary anesthesia. Its (S)-enantiomer, esketamine, similarly employed for anesthesia analgesia. The anesthetic effects of ketamine esketamine arise from their antagonism the N-methyl-D-aspartate receptor (NMDAR). In field psychiatry, rapid-acting antidepressant properties severe depression have generated significant interest, resulting its increased off-label usage United States (U.S.). 2019, nasal spray received approval use U.S. Europe. However, concerns emerged regarding potential adverse effects, including long-term efficacy, addiction risks, suicide risk clinical settings. contrast, arketamine, (R)-enantiomer ketamine, exhibits superior longer-lasting rodent models depression, with fewer side compared to esketamine. Nevertheless, research on efficacy safety arketamine patients remains limited. This article provides concise exploration historical two enantiomers while also delving into future directions application these fields.
Язык: Английский
Процитировано
11
British Journal of Anaesthesia, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
1
European Journal of Pharmacology, Год журнала: 2024, Номер 985, С. 177096 - 177096
Опубликована: Ноя. 3, 2024
The novel antidepressant arketamine, the (R)-enantiomer of ketamine, has been shown to ameliorate demyelination and facilitate remyelination in brains cuprizone (CPZ)-treated mice. However, mechanisms behind its effects remain unclear. Given role transforming growth factor β1 (TGF-β1) arketamine's antidepressant-like effects, we examined whether TGF-β1 also plays a on CPZ-treated Additionally, investigated intranasal these Repeated intermittent administration arketamine (10 mg/kg/day, twice weekly for last 2-weeks) attenuated corpus callosum (CC) CPZ (6 weeks)-treated Furthermore, pretreatment with RepSox mg/kg/day), an inhibitor TGF-β receptor 1, significantly blocked beneficial CC repeated (3.0 μg/kg/day, 2 weeks) ameliorated facilitated These data suggest that can mitigate facilitates mice through TGF-β1-dependent mechanism.
Язык: Английский
Процитировано
6
Translational Psychiatry, Год журнала: 2025, Номер 15(1)
Опубликована: Фев. 6, 2025
Suicide is a global public health problem with few empirically supported treatments. We conducted systematic review of clinical trials (CT) since 2020 racemic ketamine or one its enantiomers' (R/S) potential to reduce suicidal ideation behavior (SIB). An initial PubMed search on April 15th, 2024 yielded 2483 results. 104 relevant CTs were identified. additional using other engines March 19th, 52 sources. After screening, 14 RCTs met the inclusion criteria which required clinically significant SIB among participants, enantiomers as an anti-SIB treatment, and outcome. excluded neuroimaging studies, meta-analyses, reviews, case reports. Open-label studies also except in R-ketamine where we included 2 open due limited published data for this enantiomer, yielding total 16 CTs. used Revised Cochrane risk-of-bias tool RCTs. reviewed had (SI) but none The include augmentation treatments such electroconvulsive therapy (ECT), various routes administration – intravenous (IV), intramuscular (IM), intranasal (IN) single versus multiple dose designs. Multiple doses IV ketamine/S-ketamine produced reductions SI periods several days weeks, while showed shorter, more variable effects. IN less consistent anti-SI appears be well tolerated. produce fewer side effects, research needed clarify antidepressant effects humans. This affirms time-limited, need personalized treatment. Limitations study heterogeneity, small samples, paucity R-ketamine.
Язык: Английский
Процитировано
0
Asian Journal of Psychiatry, Год журнала: 2025, Номер unknown, С. 104502 - 104502
Опубликована: Апрель 1, 2025
Язык: Английский
Процитировано
0
Asian Journal of Psychiatry, Год журнала: 2024, Номер 99, С. 104164 - 104164
Опубликована: Июль 21, 2024
In Japan, the landscape of clinical practice for substance use disorder is changing significantly, primarily due to an increase in patients using over-the-counter drugs. A major concern rising number misusing dextromethorphan (DXM). These with DXM disorders often have severe trauma-related and mood symptoms, therefore try cope those symptoms by self-medicating DXM. this article, we propose that ketamine, which has similar psychopharmacological effects DXM, may be a useful alternative pharmacological treatment these patients.
Язык: Английский
Процитировано
1
Biochemical Pharmacology, Год журнала: 2024, Номер 229, С. 116516 - 116516
Опубликована: Авг. 30, 2024
Язык: Английский
Процитировано
1
Biomedicines, Год журнала: 2024, Номер 12(10), С. 2283 - 2283
Опубликована: Окт. 9, 2024
Research over the past years has compared enantiomers (S)-ketamine (esketamine) and (R)-ketamine (arketamine) of previously known racemic mixture called ketamine (R/S-ketamine). Esketamine been found to be more potent, offering three times stronger analgesic effects 1.5 greater anesthetic efficacy than arketamine. It provides smoother anesthesia with fewer side is widely used in clinical settings due its neuroprotective, bronchodilatory, antiepileptic properties. Approved by FDA EMA 2019, esketamine currently alongside SSRIs or SNRIs for treatment-resistant depression (TRD). On other hand, arketamine shown potential treating neurological disorders such as Alzheimer's, Parkinson's, multiple sclerosis, possible antidepressant anti-inflammatory benefits. While already use, arketamine's future depends on further research address safety, efficacy, optimal dosing. Both hold significant value, excelling anesthesia, showing promise psychiatric treatments.
Язык: Английский
Процитировано
1
Asian Journal of Psychiatry, Год журнала: 2024, Номер 106, С. 104351 - 104351
Опубликована: Дек. 21, 2024
Язык: Английский
Процитировано
1
Pharmacology Biochemistry and Behavior, Год журнала: 2024, Номер unknown, С. 173882 - 173882
Опубликована: Окт. 1, 2024
Язык: Английский
Процитировано
0